Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Practical implementation of automated insulin delivery systems in 2025: A French position statement update.
Diabetes Metab
March 2025
Université Grenoble Alpes, INSERM U1055, LBFA, Endocrinologie, CHU Grenoble Alpes, France.
The advent of automated insulin delivery (AID) systems in 2020 marked a disruptive event in managing type 1 diabetes, benefiting children and adults alike. By 2024, advances in real-world data and research motivated an update to the French consensus on AID systems to expand accessibility, refine guidelines, and optimize patient follow-up. AID systems have consistently improved glycemic control by reducing HbA1c, increasing time-in-range (TIR), and minimizing hypoglycemia, with significant benefits even for specific populations such as individuals with poor glycemic control, brittle diabetes, children, very young children, pregnant women, those with insulin resistance or gastroparesis, or after bariatric surgery.
View Article and Find Full Text PDFFrom Concept to Cure: The Evolution of CAR-T Cell Therapy.
Mol Ther
March 2025
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, 19104, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer immunotherapy in the 21 century, providing innovative solutions and life-saving therapies for previously untreatable diseases. This approach has shown remarkable success in treating various hematologic malignancies and is now expanding into clinical trials for solid tumors, such as prostate cancer and glioblastoma, as well as infectious and autoimmune diseases. CAR-T cell therapy involves harvesting a patient's T cells, genetically engineering them with viral vectors to express CARs targeting specific antigens and reinfusing the modified cells into the patient.
View Article and Find Full Text PDFIn-situ adsorption-coupled-oxidation enabled mercury vapor capture over sp-hybridized graphdiyne.
Nat Commun
March 2025
Institute of Environmental and Applied Chemistry, College of Chemistry, Central China Normal University, Wuhan, PR China.
Developing efficient and sustainable carbon sorbent for mercury vapor (Hg) capture is significant to public health and ecosystem protection. Here we show a carbon material, namely graphdiyne with accessible sp-hybridized carbons (HsGDY), that can serve as an effective "trap" to anchor Hg atoms by strong electron-metal-support interaction, leading to the in-situ adsorption-coupled-oxidation of Hg. The adsorption process is benefited from the large hexagonal pore structure of HsGDY.
View Article and Find Full Text PDFExploring the peroxidase-like activity of 4Fe-Ni-B nanoparticles for analytical sensing.
RSC Adv
March 2025
Chongqing Key Laboratory of Green Catalysis Materials and Technology, College of Chemistry, Chongqing Normal University Chongqing 401331 China
Natural enzymes, despite their superior catalytic proficiency, are frequently constrained by their environmental sensitivity and the intricacies associated with their extraction and preservation. Consequently, there has been a significant impetus in the scientific community to develop robust, economical, and accessible enzyme mimics. In this context, transition metal borides have risen to prominence as auspicious contenders, capitalizing on their distinctive electronic and catalytic attributes to replicate the functionalities of natural enzymes.
View Article and Find Full Text PDFNovel therapeutics in refractory germ cell tumors.
Curr Opin Oncol
February 2025
Division of Hematology & Medical Oncology - Melvin & Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Purpose Of Review: Refractory germ cell tumors (GCT), those progressing after known effective salvage therapies, carry a dismal prognosis with minimal treatment options of limited efficacy. This review aims to highlight the advances in understanding refractory GCT and review upcoming and active clinical trials with novel therapeutics in development.
Recent Findings: Patients with refractory disease after optimal salvage chemotherapy are rarely cured and should be referred to centers with expertise in GCT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!